AMLX — Amylyx Pharmaceuticals, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1658551 ·
Last close
$29.85
Market Cap
$3.33B
52W High
$41.14
52W Low
$10.83
ADV30
3,008,598
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -45,693,000 | -43,423,000 | 264,564,000 | 49,326,000 | 25,397,000 |
| Mar 2026 | 0 | 0 | -43,779,000 | -41,284,000 | 293,603,000 | 229,136,000 | 20,442,000 |
| Dec 2025 | 0 | 0 | -36,605,000 | -32,999,000 | 332,645,000 | 226,651,000 | 27,386,000 |
| Sep 2025 | 0 | 0 | -36,027,000 | -34,386,000 | 362,741,000 | 225,178,000 | 30,745,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-126,577,000
Investing CF
$-78,831,000
Financing CF
$196,094,000
CapEx
$-138,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.43
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-836,134,000
Inventory
$0
Receivables
$88,000
ST Investments
$201,434,000
EBIT TTM
$-162,104,000
Pretax Income TTM
$-152,046,000
Interest Exp TTM
—
Analysts
9
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -153,291,000 | -144,735,000 | 332,645,000 | 27,386,000 | 305,259,000 | -123,343,000 |
| Dec 2024 | 87,371,000 | -255,677,000 | -301,743,000 | 193,634,000 | 28,869,000 | 164,765,000 | -167,647,000 |
| Dec 2023 | 380,786,000 | 38,802,000 | 49,271,000 | 517,454,000 | 84,022,000 | 433,432,000 | 11,919,000 |
| Dec 2022 | 22,230,000 | -201,341,000 | -198,375,000 | 391,453,000 | 50,846,000 | 340,607,000 | -179,871,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.15
Max Pain — expiry 2026-10-16 (volume-derived — Yahoo OI feed degraded)
max pain strike: $35.00 · spot: $29.85 · call volume: 650 · put volume: 1,727Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ELVN | Enliven Therapeutics, Inc. | $3.37B | $46.01 | — |
| ARQT | Arcutis Biotherapeutics, Inc. | $3.44B | $27.33 | — |
| RCUS | Arcus Biosciences, Inc. | $3.15B | $25.01 | — |
| ACAD | ACADIA PHARMACEUTICALS INC | $3.54B | $20.53 | — |
| XENE | Xenon Pharmaceuticals Inc. | $3.56B | $36.72 | — |
News headlines (Yahoo Finance, 1h cache)
Amylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic Forum
2026-09-23 13:00 · Yahoo
Tortugas Neuroscience Announces Appointment of Jim Frates to Board of Directors
2026-09-09 12:00 · Yahoo
Amylyx Pharmaceuticals to Present at the 24th Annual Morgan Stanley Global Healthcare Conference
2026-09-08 13:00 · Yahoo
Is GLP-1 Stock Amylyx Still a Buy After Skyrocketing 247%?
2026-09-01 13:50 · Yahoo
Why Amylyx Pharmaceuticals Blasted Nearly 79% Higher This Week
2026-08-21 22:00 · Yahoo
Amylyx (AMLX) Faces a Binary Phase 3 Test. Can Avexitide Rebuild the Company?
2026-08-21 21:58 · Yahoo
Why Did IOVA, AMLX And COP Stocks Surge To 52-Week Highs Today?
2026-08-21 03:57 · Yahoo
Amylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common Stock
2026-08-20 03:06 · Yahoo
Amylyx Pharmaceuticals (AMLX) Posts Phase 3 Avexitide Win And Follows With Equity Raise
2026-08-19 09:11 · Yahoo
Why Did AMLX, IOVA, OKE Stocks Hit 52-Week Highs Today?
2026-08-19 01:54 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.